Fig. 4

The IGF-1, IL-4, IL-6, or SDF-1 impact on MRF and structural protein expression in co-cultures of human BM-MSCs (hBM-MSCs) and mouse C2C12 myoblasts. a The experiment design. b The expression of human ADAM9, CD9, CDH15 (m-cadherin), VCAM, and MYH3 (muscle embryonic myosin heavy chain 3) in hBM-MSCs non-treated (NT) and treated either with IGF-1, IL-4, IL-6, or SDF-1 co-cultured with C2C12 for 7 days in the proliferating medium (PM) (n = 3). c The expression of human ADAM9, CD9, CDH15 (m-cadherin), VCAM, and MYH3 (muscle embryonic myosin heavy chain 3) in hBM-MSCs non-treated (NT) or treated with either IGF-1, IL-4, IL-6, or SDF-1 co-cultured with C2C12 myoblasts for 7 days in the differentiating medium (DM) (n = 3). d The expression of mouse Adam9, Myog, and Myh3 mRNA in C2C12 myoblasts non-treated (NT) and treated with either IGF-1, IL-4, IL-6, or SDF-1 co-cultured with hBM-MSCs for 7 days in the proliferating medium (PM) (n = 3). e The expression of mouse Adam9, Myog, and Myh3 mRNA in C2C12 myoblasts non-treated (NT) and treated with either IGF-1, IL-4, IL-6, or SDF-1 co-cultured with hBM-MSCs for 7 days in the differentiating medium (DM) (n = 3). f The expression of human ADAM9, CD9, and CDH15 (m-cadherin) in hBM-MSCs pre-treated for 3 days with either IGF-1, IL-4, IL-6, or SDF-1 and then co-cultured with C2C12 myoblasts in the proliferating medium (PM) for 7 days (n = 3); *p < 0.05, **p < 0.01, ***p < 0.005